Nonetheless, prostate cancer working group 3 (PCWG3) criteria does not encourage treatment decision making based on early PSA changes within the first 12 weeks, since flare reactions of PSA occur in approximately a third of patients treated with taxanes [19,20,21]. Here, KLK3 is linked to prostate cancer.